OvaScience (OVAS) Reaches OvaPrime and OvaTure Goals for 2015; Offers Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
OvaScience Provides Business Update and Outlines 2015 Corporate Progress
December 7, 2015 4:30 PM EST- Company Achieves 2015 OvaPrime and OvaTure Treatment Goals -
WALTHAM, Mass.--(BUSINESS WIRE)-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the Company has achieved its 2015 corporate goals for the OvaPrimeSM and OvaTureSM fertility treatments.
OvaPrime Treatment Preceptorship Program OvaScience commenced a non-commercial preceptorship program with the OvaPrime treatment at an in vitro fertilization (IVF) clinic outside of the United States to gain insight into the clinical efficacy and... More